Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-022350
Filing Date
2025-11-13
Accepted
2025-11-13 16:31:13
Documents
53
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 543299
2 EX-31.1 ex31-1.htm EX-31.1 13900
3 EX-32.1 ex32-1.htm EX-32.1 7680
  Complete submission text file 0001493152-25-022350.txt   2921369

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aneb-20250930.xsd EX-101.SCH 25993
5 XBRL CALCULATION FILE aneb-20250930_cal.xml EX-101.CAL 30860
6 XBRL DEFINITION FILE aneb-20250930_def.xml EX-101.DEF 87626
7 XBRL LABEL FILE aneb-20250930_lab.xml EX-101.LAB 242581
8 XBRL PRESENTATION FILE aneb-20250930_pre.xml EX-101.PRE 197096
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 264557
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734
Business Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40388 | Film No.: 251479101
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)